TRPM6 — Transient Receptor Potential Cation Channel Subfamily M Member 6

TRPM6 — Transient Receptor Potential Cation Channel Subfamily M Member 6

Overview

TRPM6 (Transient Receptor Potential Cation Channel Subfamily M Member 6) is a highly selective magnesium-permeable ion channel that plays a critical role in systemic and cellular magnesium homeostasis. Originally identified as the channel responsible for intestinal magnesium absorption, TRPM6 is now recognized as having important functions in the central nervous system where magnesium homeostasis is essential for neuronal function, synaptic plasticity, and protection against excitotoxicity. Mutations in TRPM6 cause familial hypomagnesemia with secondary hypocalcemia (HSH), a rare autosomal recessive disorder, while common variants have been associated with altered magnesium levels and potentially with neurodegenerative disease risk. The channel's role in maintaining intracellular magnesium makes it a potential therapeutic target for conditions ranging from cardiovascular disease to Alzheimer's disease.

TRPM6 — Transient Receptor Potential Cation Channel Subfamily M Member 6

Overview

TRPM6 (Transient Receptor Potential Cation Channel Subfamily M Member 6) is a highly selective magnesium-permeable ion channel that plays a critical role in systemic and cellular magnesium homeostasis. Originally identified as the channel responsible for intestinal magnesium absorption, TRPM6 is now recognized as having important functions in the central nervous system where magnesium homeostasis is essential for neuronal function, synaptic plasticity, and protection against excitotoxicity. Mutations in TRPM6 cause familial hypomagnesemia with secondary hypocalcemia (HSH), a rare autosomal recessive disorder, while common variants have been associated with altered magnesium levels and potentially with neurodegenerative disease risk. The channel's role in maintaining intracellular magnesium makes it a potential therapeutic target for conditions ranging from cardiovascular disease to Alzheimer's disease.

<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">TRPM6 Channel</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>TRPM6</td></tr>
<tr><td><strong>Full Name</strong></td><td>Transient Receptor Potential Cation Channel Subfamily M Member 6</td></tr>
<tr><td><strong>Chromosome</strong></td><td>9q21.13</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td>[140472](https://www.ncbi.nlm.nih.gov/gene/140472)</td></tr>
<tr><td><strong>OMIM</strong></td><td>[607214](https://omim.org/entry/607214)</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000106069</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[Q9BX63](https://www.uniprot.org/uniprot/Q9BX63)</td></tr>
<tr><td><strong>Protein Family</strong></td><td>TRP melastatin channel family</td></tr>
<tr><td><strong>Subcellular Location</strong></td><td>Plasma membrane, intestinal epithelium, kidney</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>Hypomagnesemia, Secondary Hypocalcemia, Cardiovascular Disease, Neurodegeneration</td></tr>
</table>
</div>

Gene Structure and Evolution

Genomic Organization

The TRPM6 gene is located on the long arm of chromosome 9 (9q21.13), spanning approximately 56 kb of genomic DNA. The gene consists of 39 exons that encode a protein of 2,128 amino acids, making TRPM6 one of the largest members of the TRP channel family. The genomic structure includes multiple alternative first exons that give rise to tissue-specific transcripts, allowing for differential regulation of TRPM6 expression in various tissues.

The TRPM6 promoter contains several regulatory elements:

• FOXO1 binding sites: Respond to cellular energy status
• Vitamin D response elements: Mediate 1,25(OH)₂D₃ regulation
• EGF-responsive elements: Allow epidermal growth factor modulation
• Hypoxia-responsive elements: Enable oxygen tension regulation

Evolutionary Conservation

TRPM6 shows remarkable evolutionary conservation across vertebrates, with orthologs identified in mammals, birds, reptiles, amphibians, and fish. The channel's core structure, particularly the pore region and the melastatin domain, is highly conserved, reflecting the fundamental importance of magnesium homeostasis across species. Notably, TRPM6 arose from gene duplication of the closely related TRPM7 channel, which also conducts magnesium and functions as a kinase.

Protein Structure and Function

Domain Architecture

TRPM6 possesses a complex domain organization characteristic of TRPM family channels:

The transmembrane architecture follows the canonical TRP channel layout:

• S1-S4: Voltage sensor-like domain (lacking true voltage sensitivity)
• S5-S6: Pore-forming region with selectivity filter
• Pore helix: DXP motif conferring Mg²⁺ selectivity

Ion Selectivity and Conductance

TRPM6 exhibits exceptional selectivity for magnesium over other cations:

| Ion | Relative Permeability |
|-----|---------------------|
| Mg²⁺ | 1.0 (reference) |
| Ca²⁺ | 0.03-0.05 |
| Na⁺ | 0.001 |
| K⁺ | 0.0001 |

This extreme magnesium selectivity is mediated by a conserved aspartate in the pore region (D1083) that acts as a magnesium filter. The channel conducts Mg²⁺ with a unitary conductance of approximately 40 pS under physiological conditions.

Magnesium Homeostasis Function

TRPM6 serves as the master regulator of systemic magnesium balance:

Intestinal absorption:

• Primary route for dietary magnesium uptake
• Accounts for ~60-70% of total magnesium absorption
• Active transport against electrochemical gradient
• Vitamin D-regulated expression

• Apical magnesium uptake in distal convoluted tubule
• Fine-tuning of urinary magnesium excretion
• Essential for preventing renal magnesium wasting

• Maintains intracellular Mg²⁺ at ~0.5-1 mM
• Couples to cellular energy status via Mg²⁺-ATP
• Regulates magnesium-dependent enzymes

Kinase Activity

The C-terminal serine/threonine kinase domain of TRPM6 is functional and contributes to channel regulation:

Expression and Localization

Tissue Distribution

TRPM6 shows a tissue-specific expression pattern:

High expression:

• Small intestine: Villi and crypt enterocytes (primary absorption site)
• Kidney: Distal convoluted tubule, connecting tubule
• Colon: Epithelial cells
• Testis: Spermatogonia, Leydig cells

• Brain: Neurons, astrocytes (region-specific)
• Heart: Cardiac myocytes
• Lung: Alveolar epithelium
• Liver: Hepatocytes

• Skeletal muscle
• Peripheral blood cells
• Adipose tissue

Subcellular Localization

TRPM6 localizes primarily to the apical membrane of polarized epithelial cells:

• Intestine: Apical brush border membrane
• Kidney: Apical membrane of distal tubule cells
• Brain: Somatodendritic compartment of neurons

Brain Expression Patterns

Within the central nervous system, TRPM6 expression varies by region:

• Hippocampus: High in CA1 pyramidal neurons, dentate granule cells
• Cerebral cortex: Layer-specific expression in pyramidal neurons
• Cerebellum: Purkinje cells show prominent expression
• Substantia nigra: Moderate expression in dopaminergic neurons
• Brainstem: Variable expression in motor and sensory nuclei

Role in Neurodegeneration

Magnesium in Neuronal Health

Magnesium is essential for numerous neuronal processes:

Alzheimer's Disease (AD)

TRPM6 and magnesium homeostasis may influence AD pathogenesis through multiple mechanisms:

Amyloid processing:

• Magnesium affects amyloid precursor protein (APP) processing
• Low magnesium favors amyloidogenic Aβ production
• Magnesium chelation reduces Aβ toxicity in vitro
• Clinical studies show reduced CSF magnesium in AD patients

• Magnesium-dependent kinases regulate tau phosphorylation
• Mg²⁺ deficiency may alter tau kinase/phosphatase balance
• NFTs contain altered metal homeostasis

• Synaptic plasticity requires magnesium
• Low magnesium impairs LTP in hippocampal slices
• Aβ reduces synaptic magnesium uptake

• Magnesium modulates microglial activation
• Anti-inflammatory effects of magnesium supplementation
• Reduced neuroinflammation with magnesium treatment

• Several studies show decreased serum/CSF magnesium in AD
• Magnesium deficiency correlates with cognitive decline
• Magnesium supplementation has shown mixed results in clinical trials

Parkinson's Disease (PD)

TRPM6 involvement in PD relates to dopaminergic neuron vulnerability:

Dopaminergic neuron susceptibility:

• High metabolic demand requires efficient magnesium handling
• Mitochondrial function depends on Mg²⁺
• Dopamine oxidation produces reactive species requiring magnesium-dependent antioxidant systems

• Magnesium affects protein aggregation kinetics
• Low magnesium may promote α-syn oligomerization
• Metal binding to α-synuclein influences aggregation

• Mg²⁺ is essential for mitochondrial ATP production
• Complex I activity requires magnesium
• PD brains show mitochondrial dysfunction

• MPTP models show altered magnesium homeostasis
• 6-OHDA models demonstrate magnesium dysregulation
• Magnesium supplementation protects dopaminergic neurons

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence links TRPM6 to motor neuron disease:

Excitotoxicity:

• Magnesium modulates NMDA receptor activity
• Dysregulated magnesium may contribute to excitotoxic cell death
• ALS motor neurons show increased excitability

• Motor neurons have high energy demands
• Magnesium-ATP is critical for cellular viability
• TRPM6 dysfunction may impair metabolic regulation

• TRPM6 regulates cellular magnesium that influences calcium handling
• Magnesium protects against calcium-induced toxicity
• Altered magnesium may contribute to calcium dysregulation

Other Neurodegenerative Conditions

TRPM6 may play roles in:

Epilepsy:

• Magnesium blocks NMDA receptors
• TRPM6 mutations associated with seizure susceptibility
• Magnesium supplementation used in seizure control

• Myelin maintenance requires magnesium
• Demyelinating lesions show altered magnesium
• Clinical trials of magnesium in MS

• Magnesium deficiency common in migraine
• TRPM6 variants associated with migraine risk
• Magnesium prophylaxis effective in some patients

Interaction Network

Protein-Protein Interactions

TRPM6 interacts with several cellular proteins:

Channel partners:

• TRPM7: Heterotetramer formation, complementary magnesium transport
• Spectrin: Cytoskeletal anchoring
• Ankyrin G: Membrane domain organization

• MagT1: Magnesium transporter, affects TRPM6 function
• NCS1: Neuronal calcium sensor, modulates channel activity
• Calmodulin: Calcium-dependent regulation

• PI3K/Akt pathway: Growth factor regulation
• AMPK: Energy status sensing
• mTOR: Nutrient signaling

Signaling Pathway Integration

TRPM6 integrates with key cellular signaling pathways:

Therapeutic Implications

Magnesium Supplementation

The relationship between TRPM6 and magnesium has therapeutic implications:

Neurodegeneration trials:

• Alzheimer's disease: Mixed results in cognitive outcomes
• Parkinson's disease: Some benefit in motor function
• Vascular dementia: Positive effects on cognition

• Blood-brain barrier penetration
• Dose optimization
• Individual variation in absorption
• TRPM6 function affects supplementation efficacy

Small Molecule Modulators

Targeting TRPM6 directly:

• Magnesium l-threonate: Enhanced brain penetration
• Novel TRPM6 activators in development

• Block excessive magnesium uptake
• Potential in certain cancers

• Vitamin D optimization
• TRPM6 expression enhancers

Gene Therapy Approaches

Emerging therapeutic modalities:

• TRPM6 overexpression: Increase neuronal magnesium handling
• Variant-specific targeting: Correct specific mutations
• Cell-type specificity: Neuronal vs. systemic effects

Animal Models

Knockout Mouse

Trpm6 knockout mice are embryonic lethal, demonstrating its essential role:

• Die around embryonic day 13.5-15.5
• Show severe developmental defects
• Magnesium homeostasis completely disrupted
• Neural tube defects

Heterozygous and Conditional Models

More useful models for neurodegeneration:

Trpm6⁺/⁻ mice:

• Reduced magnesium absorption
• Hypomagnesemia without lethality
• Increased susceptibility to metabolic stress

• Intestinal-specific deletion: Normal viability, magnesium malabsorption
• Neuron-specific deletion: Being characterized for neurodegeneration phenotypes

Transgenic Models

Overexpression and mutant models:

• Neuronal TRPM6 overexpression: Improved neuronal magnesium
• HSH mutant TRPM6: Dominant-negative effects
• Humanized mouse models for variant testing

Research Directions

Current Questions

Key research areas for TRPM6 in neurodegeneration:

Emerging Approaches

• Single-cell RNAseq: Neuronal TRPM6 expression patterns
• Cryo-EM structure: High-resolution channel structure
• CRISPR models: Precise genetic modifications
• Patient-derived neurons: iPSC models of TRPM6 variants

Cross-Links

TRPM6 connects to multiple NeuroWiki pages:

• [Magnesium Homeostasis](/mechanisms/magnesium-homeostasis)
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Amyotrophic Lateral Sclerosis](/diseases/als)
• [NMDA Receptor Signaling](/mechanisms/nmda-receptor-signaling)
• [Synaptic Plasticity](/mechanisms/synaptic-plasticity)
• [Excitotoxicity](/mechanisms/excitotoxicity)
• [TRPM7 Channel](/proteins/trpm7-protein)
• [Calcium Signaling](/mechanisms/calcium-signaling)
• [Mitochondrial Function](/mechanisms/mitochondrial-dysfunction)

References

Appendix: Clinical and Research Resources

Diagnostic Testing

TRPM6 genetic testing is available:

• Clinical testing: NGS panels, exome sequencing
• Research testing: Functional assays, expression studies
• Interpretation: HSH-causing variants vs. common variants

Variant Classification

TRPM6 variants are classified:

• Pathogenic: HSH-causing loss-of-function variants
• Likely pathogenic: Strong computational evidence
• VUS: Common variants, uncertain significance
• Benign: Population variants, no functional impact

Therapeutic Development Pipeline

Current approaches:

• Preclinical: TRPM6 modulators, magnesium formulations
• Clinical trials: Magnesium supplementation in AD/PD
• Phase I/II: Safety and efficacy studies
• Phase III: Registration trials needed